Fengzhen Mo

机构：Guangxi Medical University · ORCID：0009-0006-5381-9273

发表论文 23 篇 · 总被引 677 次 · h-index 16

代表论文

• The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide (2018 · Theranostics · 被引 104)
• Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy (2021 · Signal Transduction and Targeted Therapy · 被引 81)
• Fusion of Dendritic Cells and Cancer-Associated Fibroblasts for Activation of Anti-Tumor Cytotoxic T Lymphocytes (2018 · Journal of Biomedical Nanotechnology · 被引 45)
• <p>In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice</p> (2020 · International Journal of Nanomedicine · 被引 44)
• A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine (2021 · Cancer Letters · 被引 40)
• Screening and antitumor effect of an anti‑CTLA‑4 nanobody (2017 · Oncology Reports · 被引 39)